IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v10y2019i1d10.1038_s41467-019-12141-5.html
   My bibliography  Save this article

Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery

Author

Listed:
  • S. Rahima Benhabbour

    (University of North Carolina at Chapel Hill
    Division of Pharmacoengineering and Molecular Pharmaceutics)

  • Martina Kovarova

    (University of North Carolina at Chapel Hill)

  • Clinton Jones

    (Division of Pharmacoengineering and Molecular Pharmaceutics)

  • Daijha J. Copeland

    (Division of Pharmacoengineering and Molecular Pharmaceutics)

  • Roopali Shrivastava

    (University of North Carolina at Chapel Hill)

  • Michael D. Swanson

    (University of North Carolina at Chapel Hill)

  • Craig Sykes

    (University of North Carolina at Chapel Hill)

  • Phong T. Ho

    (University of North Carolina at Chapel Hill)

  • Mackenzie L. Cottrell

    (University of North Carolina at Chapel Hill)

  • Anush Sridharan

    (University of North Carolina at Chapel Hill)

  • Samantha M. Fix

    (Division of Pharmacoengineering and Molecular Pharmaceutics)

  • Orrin Thayer

    (University of North Carolina at Chapel Hill)

  • Julie M. Long

    (University of North Carolina at Chapel Hill)

  • Daria J. Hazuda

    (Merck Research Laboratories)

  • Paul A. Dayton

    (University of North Carolina at Chapel Hill)

  • Russell J. Mumper

    (University of Georgia, Office of the Provost)

  • Angela D. M. Kashuba

    (University of North Carolina at Chapel Hill)

  • J. Victor Garcia

    (University of North Carolina at Chapel Hill)

Abstract

Here we report an ultra-long-acting tunable, biodegradable, and removable polymer-based delivery system that offers sustained drug delivery for up to one year for HIV treatment or prophylaxis. This robust formulation offers the ability to integrate multiple drugs in a single injection, which is particularly important to address the potential for drug resistance with monotherapy. Six antiretroviral drugs were selected based on their solubility in N-methyl-2-pyrrolidone and relevance as a combination therapy for HIV treatment or prevention. All drugs released with concentrations above their protein-adjusted inhibitory concentration and retained their physical and chemical properties within the formulation and upon release. The versatility of this formulation to integrate multiple drugs and provide sustained plasma concentrations from several weeks to up to one year, combined with its ability to be removed to terminate the treatment if necessary, makes it attractive as a drug delivery platform technology for a wide range of applications.

Suggested Citation

  • S. Rahima Benhabbour & Martina Kovarova & Clinton Jones & Daijha J. Copeland & Roopali Shrivastava & Michael D. Swanson & Craig Sykes & Phong T. Ho & Mackenzie L. Cottrell & Anush Sridharan & Samantha, 2019. "Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery," Nature Communications, Nature, vol. 10(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-12141-5
    DOI: 10.1038/s41467-019-12141-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-019-12141-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-019-12141-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Manse Kim & Claire E. Johnson & Alan A. Schmalstig & Ayano Annis & Sarah E. Wessel & Brian Horn & Amanda Schauer & Agata A. Exner & Jason E. Stout & Angela Wahl & Miriam Braunstein & J. Victor Garcia , 2022. "A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis," Nature Communications, Nature, vol. 13(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-12141-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.